StoneCrest Wealth Management Inc. Acquires 11,671 Shares of Scholar Rock Holding Corporation $SRRK

StoneCrest Wealth Management Inc. raised its holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 24.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 59,003 shares of the company’s stock after buying an additional 11,671 shares during the quarter. StoneCrest Wealth Management Inc. owned 0.06% of Scholar Rock worth $2,494,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Scholar Rock by 1.1% during the third quarter. Vanguard Group Inc. now owns 4,914,927 shares of the company’s stock worth $183,032,000 after buying an additional 53,333 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after acquiring an additional 2,521,022 shares during the last quarter. Bellevue Group AG increased its position in Scholar Rock by 10.1% during the third quarter. Bellevue Group AG now owns 3,244,537 shares of the company’s stock worth $120,827,000 after acquiring an additional 297,242 shares during the period. Eventide Asset Management LLC raised its stake in Scholar Rock by 9.5% during the 2nd quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company’s stock valued at $103,192,000 after purchasing an additional 251,638 shares during the last quarter. Finally, Holocene Advisors LP acquired a new position in Scholar Rock during the 3rd quarter valued at $91,670,000. 91.08% of the stock is owned by institutional investors.

Scholar Rock Trading Up 1.3%

Shares of SRRK stock opened at $50.01 on Friday. Scholar Rock Holding Corporation has a 52-week low of $22.71 and a 52-week high of $50.50. The stock has a market cap of $5.75 billion, a price-to-earnings ratio of -14.58 and a beta of 0.68. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.95 and a current ratio of 6.95. The firm has a fifty day moving average of $45.22 and a 200-day moving average of $40.75.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.10. During the same quarter last year, the business earned ($0.64) EPS. On average, equities research analysts forecast that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Keith Woods sold 16,746 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $715,054.20. Following the sale, the chief operating officer directly owned 583,254 shares in the company, valued at approximately $24,904,945.80. This represents a 2.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Mo Qatanani sold 14,898 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $46.71, for a total value of $695,885.58. Following the transaction, the insider owned 85,660 shares of the company’s stock, valued at $4,001,178.60. This trade represents a 14.82% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 207,464 shares of company stock valued at $9,157,423. 13.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $58.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 3rd. Barclays increased their target price on shares of Scholar Rock from $52.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday, March 3rd. Piper Sandler boosted their price target on Scholar Rock from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, March 4th. Finally, Wedbush upped their price target on Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a report on Wednesday. Four analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $54.93.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).